All News

From Dick Vitale receiving the Jimmy V Award at the 2022 ESPYs to a former triathlon champion opening up about his cancer experience, here’s what’s happening in the cancer space this week.

Watch Elisabeth King, from City of Hope, discuss biomarker testing during the CURE Educated Patient Lung Cancer Summit.

Treatment with FOLFIRINOX, a combination of several chemotherapy agents, prior to the surgical resection of pancreatic cancer increased survival outcomes when compared to historical data.

Investigators are analyzing the novel drug, OP-1250, both as a single-agent treatment option and in combination with Ibrance in patients with recurrent, locally advanced or metastatic ER-positive/HER2-negative breast cancer.

After experiencing complications from breast reconstruction, I’ve decided to go “fabulously flat” and evict my implants.

Findings from previous studies have shown that patients with blood cancers have been less likely to produce antibodies that protect them against COVID-19 after vaccination, but new research indicates that the booster shot may help.

Watch Dr. Farhad Mazdisnian, Dr. Terence Williams and Dr. Antoinette J. Wozniak answer questions about the basics of the disease during the CURE Educated Patient Lung Cancer Summit.

Adding Rivoceranib to pegylated liposomal doxorubicin — a type of chemotherapy — improved survival outcomes for patients with platinum-resistant ovarian cancer, according to recent study results.

The addition of Keytruda to chemoradiation, followed by maintenance Keytruda, did not lead to a statistically significant event-free survival benefit in patients with locally advanced head and neck squamous cell carcinoma.

Even in the public health shadows of the more common cancers like breast cancer, for the few but strong patients with a sarcoma diagnosis, we are obligated to spread awareness, restore hope and with specialist care, ensure the best possible outcomes.

Watch Dr. Terrance M. Williams, from City of Hope, discuss radiation advances during the CURE Educated Patient Lung Cancer Summit.

A first-in-human trial is investigating the safety and efficacy of the novel CAR-T cell therapy in patients relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

An esophageal cancer survivor noted that recovering from surgery to treat the disease was “grueling,” but he said he was eventually able to return to some normalcy with his ability to eat his favorite foods.

As I reflect on cancer survivorship, I notice how important the camraderie with fellow survivors is.

ART27.13 may help increase appetite in patients undergoing cancer treatment.

Watch Dr. Farhard Mazdisnian, from City of Hope, discuss diagnosing early, locally advanced and metastatic disease, during the CURE Educated Patient Lung Cancer Summit.

At first, I was apprehensive about a male doctor treating my breast cancer, but I soon realized that he was treating me as he would his own family members — and that made me realize that I was in good hands.

I frequently relive the day I was diagnosed with cancer and realized that I may need to limit my exposure to other people’s cancer battles.

Cosela tended to decrease myelosuppressive events — when the bone marrow is not working sufficiently to produce blood cells and platelets — in patients receiving chemotherapy for extensive-stage small cell lung cancer.

Beyond its lessons, cancer has also brought, along with the fear and anxiety, a conviction to empower myself and to create a life that I deserve: One in which joy can triumph over that fear and that anxiety.

Watch Dr. Jedd D. Wolchok, Lorenzo Cohen, Dr. Anna C. Pavlick and Julie Bain answer questions about treating skin cancer, during the CURE Educated Patient Skin Cancer Summit.

As I enter my second year of grief and the shock and fog of the traumatic loss of my wife to cancer has waned a bit, sometimes I see things a little clearer. And one thing I do know, there was something that I did get right.

Watch Dr. Anna C. Pavlick, from Weill Cornell Medicine, discuss clinical trials during the CURE Educated Patient Skin Cancer Summit.

The first patient enrolled onto a phase 1 trial has received TCMB07, an investigational drug, for the treatment of cachexia, a severe disorder that may occur in more than half of patients with advanced-stage cancer.

If I make a wrong turn while hiking, I backtrack until I find my way again. I’ve decided that it’s OK to do the same thing when it comes to finding a cancer care team.

The safety, optimal dosage and efficacy of the investigational drug is currently being evaluated in a first-in-human trial in patients with recurrent high-grade glioblastoma, a type of spinal cord and brain cancer.

Watch Lorenzo G. Cohen, from The University of Texas MD Anderson Cancer Center, discuss integrative care during the CURE Educated Patient Skin Cancer Summit.

The FDA has permitted the manufacturer of a novel drug to continue a phase 3 clinical trial investigating the effects of treatment with a novel drug in patients with HER2/neu-positive primary breast cancer.